

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A bioreductive conjugate comprising a non-cytotoxic bioreductive moiety with linked thereto at least one therapeutic agent, and salts thereof, said conjugate being such that on bioreduction the therapeutic agent is released with generation of a species having an alkylating centre ~~and being capable of~~ so that said species undergoes ~~undergoing~~ a self-alkylation reaction to generate a non-cytotoxic residue of the bioreductive moiety.

2. (Original) A bioreductive conjugate as claimed in claim 1 of formula I:



(where A is a non-cytotoxic bioreductive moiety, each B is independently the residue of a therapeutic agent, and n is an integer) or a salt thereof.


3. (Original) A bioreductive conjugate as claimed in claim 2, wherein in formula I, n is 1 to 3.

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

4. (Currently Amended) A bioreductive conjugate as claimed in claim 2, wherein A and B are stably conjugated in an oxygenated environment and are such that following reductive activation of A, A and B detach and ~~either A is itself a stable, non-cytotoxic species, or A reacts with itself to form a stable, non-cytotoxic species.~~

5. (Previously Presented) A bioreductive conjugate as claimed in claim 1, wherein said bioreductive moiety is substantially non-mutagenic.

6. (Currently Amended) A bioreductive conjugate as claimed in claim 1 of the formula II:



(II)

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

(wherein

R^1 and R^2 independently represent hydrogen or halogen atoms, or a group R, OR, SR, NHR, NR_2 , CO_2R or CONHR;

or, alternatively, R^1 and R^2 together with the intervening ring carbon atoms form a 5-7 membered carbocyclic or heterocyclic ring itself optionally substituted by one or more halogen atoms, or by one or more groups selected from R, OR, SR, NHR, NR_2 , CO_2R and CONHR;

Z represents an alkyl, alkenyl, aryl or aralkyl group optionally carrying at least one OH, SH, NH_2 or NHR^7 group in which R^7 is an alkyl group or Z represents a group of the formula $-XH$ where X represents an oxygen or a sulphur atom, or a group of formula NY in which Y represents a hydrogen atom or an alkyl group ;

R^3 , R^4 , R^5 and R^6 independently represent hydrogen atoms or an alkyl or alkenyl group;

each group R independently represents a hydrogen atom, an alkyl or alkenyl group;

E represents the residue of a therapeutic agent to be delivered, optionally attached via a linking group L;

$m = 0, 1, 2$ or 3 ; and

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

$p = 0$ or 2;

with the proviso that when $m = 1$ then $p = 0$)

or a salt thereof.

7. (Currently Amended) A bioreductive conjugate as claimed in claim 6, wherein in formula II:

Z represents a group of the formula $(CH_2)_nXH$;

$n = 0, 1, 2$ or 3;

X represents an oxygen or sulphur atom, or a group of formula NY in which Y represents a hydrogen atom or an alkyl group;

or a salt thereof.

8. (Currently Amended) A bioreductive conjugate as claimed in claim 6, wherein in formula II:

Z represents a group of the formula ~~$(CH_2)_nXH$~~ CH_2NH_2 in which X represents an amino group;

BLAKE et al
Appl. No. 09/367,261
October 2, 2006


R^1 and R^2 each represent alkoxy groups or, together with the intervening ring carbon atoms, R^1 and R^2 form a benzene ring;

R^3 , R^4 , R^5 and R^6 each represent hydrogen atoms; and

$n = 0$, $m = 1$ and $p = 0$;

or a salt thereof.

9. (Original) A bioreductive conjugate as claimed in claim 1 of formula III:



(wherein

P and Q together with the intervening ring carbon atoms form a quinone or indoloquinone ring, a nitroaromatic, N-oxide or diazoaromatic compound, itself optionally substituted by one or more

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

halogen atoms, or by one or more groups selected from R, OR, SR, NHR, NR₂, CO₂R and CONHR;

R¹ represents a hydrogen or halogen atom, or a group R, OR, SR, NHR, NR₂, CO₂R or CONHR;

R³, R⁴ and R⁵ independently represent hydrogen atoms or an alkyl or alkenyl group;

each group R independently represents a hydrogen atom, an alkyl or alkenyl group; and

E represents the residue of a therapeutic agent to be delivered, optionally attached via a linking group L)

or a salt thereof.

10. (Original) A bioelective conjugate as claimed in claim 9, wherein in formula III:


P and Q together with the intervening ring carbon atoms form a quinone or indoloquinone ring; and

R¹, R³, R⁴ and R⁵ each represent hydrogen atoms or methyl groups;

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

or a salt thereof.

11. (Original) A bioreductive conjugate as claimed in claim 1 of formula IV:



(wherein

S and T together with the intervening ring carbon atoms form a quinone or iminoquinone ring, a nitroaromatic or N-oxide compound, itself optionally substituted by one or more halogen atoms, or by one or more groups selected from R, OR, SR, NHR, NR₂, CO₂R and CONHR;

Z represents an alkyl, alkenyl, aryl or aralkyl group optionally carrying at least one OH, SH, NH₂ or NHR⁶ group in which R⁶ is an alkyl group;

R⁷ represents an alkyl group;

R³, R⁴ and R⁵ independently represent hydrogen atoms or an alkyl or alkenyl group;

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

each group R independently represents a hydrogen atom, an alkyl or alkenyl group;

$q = 0, 1, 2$ or 3 ; and

E represents the residue of a therapeutic agent to be delivered, optionally attached via a linking group L)

or a salt thereof.

12. (Original) A bioreductive conjugate as claimed in claim 11, wherein in formula IV:

S and T together with the intervening ring carbon atoms form a quinone or N-oxide compound;

R^3 , R^4 and R^5 each represent hydrogen atoms;

R^7 is methyl;

Z represents a group of formula $(CH_2)_nXH$ wherein X represents an oxygen or sulphur atom, or X represents a group of formula NY in which Y represents a hydrogen atom or an alkyl group; and

$q = 0$ or 1 ,

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

or a salt thereof.

13. (Previously Presented) A bioreductive conjugate as claimed in claim 1, wherein said bioreductive moiety comprises a quinone, naphthoquinone, indoloquinone, quinolino quinone or a derivative thereof.

14. (Original) A bioreductive conjugate as claimed in claim 13, wherein said bioreductive moiety is a 1,4-benzoquinone, a naphthoquinone, or a derivative thereof, in which the quinone ring carries an optionally hydroxy- or aminosubstituted alkenyl group and an adjacent nucleophilic moiety.

15. (Previously Presented) A bioreductive conjugate as claimed in claim 1, wherein said bioreductive moiety is a 1,4-benzoquinone and the therapeutic agent is dexamethasone.


16. (Previously Presented) A bioreductive conjugate as claimed in claim 1, wherein said bioreductive moiety is linked to said therapeutic agent via a linker group L comprising an ester, phosphate ester, ether, amine, thiol or thiol ester group or any combination thereof.

17. (Original) A bioreductive conjugate as claimed in claim 15 wherein said linker group L is a group of the formula:



BLAKE et al
Appl. No. 09/367,261
October 2, 2006

or



(wherein n is an integer from 1 to 3;

X represents a sulphur or oxygen atom; and

R^8 and R^9 each independently represent F or Cl).

18. (Original) A bioreductive conjugate comprising a non-cytotoxic bioreductive moiety with linked thereto at least one therapeutic agent, and salts thereof, said conjugate being such that on bioreduction the therapeutic agent is released with generation of a species having a sterically hindered alkylating centre to prevent alkylation of biomolecules.

19. (Previously Presented) A process for the preparation of a bioreductive conjugate as claimed in claim 1, said process comprising linking at least one therapeutic agent to a non-cytotoxic bioreductive moiety.

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

20. (Previously Presented) A pharmaceutical composition comprising a bio-reductive conjugate as claimed in claim 1, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutical carrier or excipient.

21. (Previously Presented) A bio-reductive conjugate as claimed in claim 1 for use in a method of targeting a therapeutic agent to a site of hypoxia and/or ischemia within the human or non-human animal body.

22. (Previously Presented) A bio-reductive conjugate as claimed in claim 1 for use in the treatment of rheumatoid arthritis or other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.

23. (Previously Presented) Use of a bio-reductive conjugate as claimed in claim 1 in the manufacture of a medicament for use as a targeting agent capable of targeting a site of hypoxia and/or ischemia within the human or non-human animal body.

24. (Original) Use as claimed in claim 22 for the treatment of rheumatoid arthritis or other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.

BLAKE et al
Appl. No. 09/367,261
October 2, 2006

25. (Previously Presented) A method of targeting hypoxic and/or ischemic tissues in the human or non-human animal body, said method comprising administering to said body a bioreductive conjugate as claimed in claim 1.